Publikationen in Zusammenarbeit mit Forschern von University of Sydney (8)

2022

  1. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

2021

  1. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

    Clinical Breast Cancer, Vol. 21, Núm. 1, pp. 80-91.e7

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2018

  1. Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR trial

    Journal of Clinical Oncology, Vol. 36, Núm. 11, pp. 1073-1079

2017

  1. Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

    Annals of Surgical Oncology, Vol. 24, Núm. 2, pp. 398-406

2015

  1. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials

    The Lancet, Vol. 386, Núm. 10001, pp. 1341-1352

2014

  1. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

    The Lancet Oncology, Vol. 15, Núm. 2, pp. 156-163

2005

  1. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583